Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) insider Sean Maduck sold 11,841 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $81.42, for a total value of $964,094.22. Following the transaction, the insider directly owned 9,938 shares in the company, valued at $809,151.96. The trade was a 54.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Sean Maduck also recently made the following trade(s):
- On Tuesday, November 3rd, Sean Maduck sold 13,159 shares of Corcept Therapeutics stock. The stock was sold at an average price of $82.25, for a total transaction of $1,082,327.75.
- On Friday, October 2nd, Sean Maduck sold 24,587 shares of Corcept Therapeutics stock. The stock was sold at an average price of $116.28, for a total transaction of $2,858,976.36.
- On Thursday, October 1st, Sean Maduck sold 413 shares of Corcept Therapeutics stock. The shares were sold at an average price of $115.54, for a total value of $47,718.02.
- On Tuesday, September 1st, Sean Maduck sold 25,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $114.43, for a total value of $2,860,750.00.
- On Tuesday, August 25th, Sean Maduck sold 30,955 shares of Corcept Therapeutics stock. The shares were sold at an average price of $125.58, for a total transaction of $3,887,328.90.
- On Friday, August 14th, Sean Maduck sold 3,664 shares of Corcept Therapeutics stock. The shares were sold at an average price of $114.49, for a total transaction of $419,491.36.
- On Monday, August 10th, Sean Maduck sold 1,031 shares of Corcept Therapeutics stock. The shares were sold at an average price of $114.52, for a total transaction of $118,070.12.
Corcept Therapeutics Price Performance
Corcept Therapeutics stock opened at $72.77 on Friday. The business has a fifty day moving average price of $107.58 and a 200-day moving average price of $75.65. Corcept Therapeutics Incorporated has a 1-year low of $28.66 and a 1-year high of $126.38. The stock has a market capitalization of $7.87 billion, a price-to-earnings ratio of 57.30 and a beta of 0.54.
Hedge Funds Weigh In On Corcept Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CORT. BlackRock Inc. acquired a new position in Corcept Therapeutics in the 2nd quarter valued at approximately $1,080,964,000. Parallel Advisors LLC lifted its stake in shares of Corcept Therapeutics by 2.5% in the 1st quarter. Parallel Advisors LLC now owns 3,977,404 shares of the biotechnology company’s stock valued at $160,329,000 after purchasing an additional 96,763 shares during the last quarter. First Trust Advisors LP lifted its holdings in shares of Corcept Therapeutics by 213.5% during the first quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock worth $87,609,000 after purchasing an additional 1,480,059 shares during the period. Bank of New York Mellon Corp purchased a new position in Corcept Therapeutics during the second quarter worth about $49,185,000. Finally, Principal Financial Group Inc. lifted its holdings in shares of Corcept Therapeutics by 2.5% during the first quarter. Principal Financial Group Inc. now owns 455,248 shares of the biotechnology company’s stock worth $18,351,000 after purchasing an additional 11,156 shares during the period. Institutional investors and hedge funds own 93.61% of the company’s stock.
Corcept Therapeutics News Roundup
Here are the key news stories impacting Corcept Therapeutics this week:
- Positive Sentiment: HC Wainwright maintained its Buy rating and $165 price target, while projecting substantial longer-term earnings growth, including $6.76 per share in FY2028 and $12.92 in FY2030. HC Wainwright recommendations
- Negative Sentiment: HC Wainwright lowered EPS estimates across several upcoming quarters and years: FY2026 to $2.05 from $2.15 and FY2027 to $3.39 from $3.95, with cuts also to its Q4 2026 and 2027 quarterly forecasts. These downward revisions may temper expectations despite the analyst’s bullish rating. HC Wainwright recommendations
- Negative Sentiment: Insiders Roberto Vieira and Sean Maduck sold substantial portions of their holdings in transactions disclosed this week. Insider sales can raise investor concerns, though they do not necessarily reflect the company’s outlook. Insider selling report
Analyst Upgrades and Downgrades
CORT has been the topic of a number of analyst reports. Truist Financial assumed coverage on shares of Corcept Therapeutics in a report on Tuesday, August 18th. They set a “buy” rating and a $164.00 price objective on the stock. Weiss Ratings upgraded Corcept Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday. Canaccord Genuity Group upped their target price on Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 target price for the company. in a report on Monday, July 27th. Finally, Zacks Research lowered shares of Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 27th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $139.50.
View Our Latest Research Report on CORT
Corcept Therapeutics Company Profile
Corcept Therapeutics Incorporated (NASDAQ:CORT) is a commercial-stage biopharmaceutical company focused on developing medicines that selectively modulate the glucocorticoid receptor. The company’s research is based on the role of excess cortisol in metabolic, psychiatric, oncologic and other serious medical conditions.
Corcept’s primary marketed product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.
Further Reading
- Five stocks we like better than Corcept Therapeutics
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
